Anticoagulation Bridging in Patients With Left Ventricular Assist Device: A Regional Analysis of HeartMate 3 Recipients

ASAIO J. 2024 Feb 1;70(2):93-98. doi: 10.1097/MAT.0000000000002067. Epub 2023 Oct 20.

Abstract

Advances in left ventricular assist device technologies have led to an improvement in pump hemocompatibility and outcomes. Because of concerns of thromboembolic complications in prior generations of left ventricular assist devices, bridging with parenteral anticoagulants was routinely. Management strategies of subtherapeutic INRs and their effects on the current generation of devices deserve review. We performed analysis of the MOMENTUM 3 trial including 6 centers in the mid-America region. Patients with subtherapeutic INRs (INR < 2) occurring after the index admission underwent chart review to determine the management strategies taken by clinicians. Strategies were divided into two groups, bridging or nonbridging. Of the 225 patients included in the analysis, 130 (58%) patients had a total of 235 subtherapeutic international normalized ratio (INR) events. Most (n = 179, 76.2%) of these INRs were not bridged (n = 100 warfarin dose adjustment, n = 79 no change in warfarin dose). Among those INRs (n = 56, 23.8%) treated with bridging, approximately half (n = 30, 53.6%) were treated with subcutaneous agents and other half (n = 26, 46.4%) were treated with intravenous agents. There was no difference in individual outcomes or composite endpoints of death, rehospitalization, CVA, or bleeding events between the groups.

MeSH terms

  • Anticoagulants / therapeutic use
  • Heart-Assist Devices* / adverse effects
  • Hemorrhage / etiology
  • Humans
  • International Normalized Ratio
  • Retrospective Studies
  • Thromboembolism* / etiology
  • Thromboembolism* / prevention & control
  • Warfarin / therapeutic use

Substances

  • Warfarin
  • Anticoagulants